{
  "schemaVersion": "2.1",
  "datasetVersion": "2026-09-11.1",
  "generatedAt": "2026-09-11",
  "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.",
  "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.",
  "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.",
  "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.",
  "changeLogPath": "/corrections#correction-ledger",
  "contactPath": "/corrections",
  "dataset": "peptide-evidence-checker-record",
  "canonicalPath": "/peptides/teriparatide",
  "canonicalUrl": "https://thepeptidefield.com/peptides/teriparatide",
  "record": {
    "slug": "teriparatide",
    "name": "Teriparatide",
    "aliases": [
      "Forteo",
      "PTH 1-34",
      "recombinant human parathyroid hormone 1-34"
    ],
    "className": "Parathyroid hormone analogue",
    "family": "Bone and tissue peptide medicines",
    "sequenceLabel": "34 amino acids · recombinant PTH fragment",
    "tier": "Established",
    "evidenceContext": "Approved human outcomes",
    "statusLine": "FDA-approved products exist for specific osteoporosis populations",
    "productContext": "The evidence applies to specific approved products and groups of people. Teriparatide evidence concerns approved drug products and labeled osteoporosis populations, not every product called PTH 1-34 or every type of fracture.",
    "approvedProducts": [
      "Forteo",
      "approved teriparatide products"
    ],
    "productRecords": [
      {
        "name": "Forteo",
        "formulation": "Prefilled delivery device",
        "route": "Subcutaneous",
        "indicationScope": "Osteoporosis uses in the high-fracture-risk populations defined in the product label.",
        "labelUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021318s057lbl.pdf",
        "labelRevision": "2024 label"
      }
    ],
    "indications": [
      "Osteoporosis treatment in labeled high-fracture-risk populations"
    ],
    "profile": {
      "humanOutcomes": {
        "level": "Strong",
        "note": "Randomized evidence supports vertebral and nonvertebral fracture-risk reduction in defined osteoporosis populations."
      },
      "humanPharmacology": {
        "level": "Strong",
        "note": "Bone-turnover, exposure, and product-specific pharmacology are well characterized."
      },
      "safetyKnowledge": {
        "level": "Strong",
        "note": "Labels describe hypercalcemia, orthostatic hypotension, osteosarcoma risk factors, and other precautions."
      },
      "productCertainty": {
        "level": "Strong",
        "note": "High for authentic approved products used within the label."
      }
    },
    "oneLine": "An established osteoporosis medicine that can reduce fracture risk in defined groups. Its evidence does not apply to every fracture-healing claim.",
    "reviewedAt": "July 23, 2026",
    "reviewedAtISO": "2026-07-23",
    "reviewHistory": [
      {
        "date": "2026-07-23",
        "note": "Initial brief based on the current Forteo label and fracture-prevention trial record."
      }
    ],
    "whatItIs": "Teriparatide is a 34-amino-acid piece of human parathyroid hormone. It is used as a prescription medicine to help build bone in osteoporosis.",
    "whatWeKnow": "Controlled trials and approved labeling support fewer spine and non-spine fractures in defined osteoporosis groups at high fracture risk.",
    "whatWeDoNotKnow": "This evidence does not prove faster healing for every new fracture, universal benefit in athletes, or safety outside monitored prescription use.",
    "antiDoping": null,
    "safetyBoundary": "The label has important limits on duration, risk factors, calcium, and monitoring. No dose, injection, or off-label fracture-healing instructions are provided.",
    "relatedSlugs": [
      "abaloparatide"
    ],
    "claims": [
      {
        "claim": "“Teriparatide reduces fracture risk in defined osteoporosis populations.”",
        "verdict": "Supported with scope",
        "explanation": "The pivotal evidence and label support vertebral and nonvertebral fracture-risk reduction in studied high-risk populations.",
        "category": "Clinical outcomes",
        "evidenceBasis": "Randomized human outcomes",
        "scope": "Labeled osteoporosis populations at high fracture risk.",
        "sourceUrls": [
          "https://pubmed.ncbi.nlm.nih.gov/11248153/",
          "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021318s057lbl.pdf"
        ]
      },
      {
        "claim": "“Teriparatide is proven to heal every fracture faster.”",
        "verdict": "Not established",
        "explanation": "Fracture prevention and acute fracture healing are different endpoints, and trial results vary by fracture setting.",
        "category": "Performance and recovery",
        "evidenceBasis": "Randomized human outcomes",
        "scope": "Acute fracture-healing outcomes across all fracture types.",
        "sourceUrls": [
          "https://pubmed.ncbi.nlm.nih.gov/26932738/"
        ]
      },
      {
        "claim": "“Because teriparatide is a peptide, it has no serious risks.”",
        "verdict": "Misleading",
        "explanation": "The current label includes clinically important warnings, precautions, and population restrictions.",
        "category": "Safety",
        "evidenceBasis": "Regulatory or product record",
        "scope": "Approved teriparatide product use.",
        "sourceUrls": [
          "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021318s057lbl.pdf"
        ]
      }
    ],
    "sources": [
      {
        "label": "FORTEO (teriparatide) prescribing information",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021318s057lbl.pdf",
        "kind": "Drug label",
        "year": 2024,
        "accessedAt": "2026-07-23"
      },
      {
        "label": "Parathyroid hormone for postmenopausal osteoporosis",
        "publisher": "PubMed · New England Journal of Medicine",
        "url": "https://pubmed.ncbi.nlm.nih.gov/11248153/",
        "kind": "Randomized trial",
        "year": 2001,
        "accessedAt": "2026-07-23"
      },
      {
        "label": "Teriparatide and femoral-neck fracture healing",
        "publisher": "PubMed · Clinical Orthopaedics and Related Research",
        "url": "https://pubmed.ncbi.nlm.nih.gov/26932738/",
        "kind": "Randomized trial",
        "year": 2016,
        "accessedAt": "2026-07-23"
      }
    ],
    "antiDopingReview": {
      "status": "Not assessed",
      "detail": "This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.",
      "sourceUrl": null,
      "reviewedAtISO": "2026-07-23"
    }
  }
}